Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Takeda Pharmaceutical Company Limited
  6. News
  7. Analyst Reco.
    4502   JP3463000004

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-07-05 am EDT
3838.00 JPY   +0.68%
07/01Takeda's Takhzyro Shows 94.8% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial in Children
MT
06/30TAKEDA PHARMACEUTICAL : Phase 3 SPRING study data presented at EAACI
PU
06/30Takeda's TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
2021TAKEDA PHARMACEUTICAL : Morgan Stanley Downgrades Takeda Pharmaceutical to Equal-weight Fr..
MT
2020TAKEDA PHARMACEUTICAL : Japan's Takeda says drug pipeline to lift sales to $48 billion in ..
RE
2018Takeda clears key hurdle as investors back $59 billion Shire deal
RE
2018Takeda investors back $59 billion Shire deal, but wary of debt load
RE
2018Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favour
RE
2018Takeda shareholders bin proposal from anti-Shire group; only 10 percent in favor
RE
2018Japan's Takeda clinches £45.3 billion Shire deal as pharma M&A rolls on
RE
2018Overshadowed by Takeda bid, Shire reports solid start to year
RE
2018Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018Shire willing to back $64 billion Takeda bid, market signals doubts
RE
2018Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018Shire rejects $63 billion Takeda bid as Allergan drops pursuit
RE
2018Drugmaker Shire soars as Japan's Takeda considers bid
RE
2018Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion
RE
2017BAYER : Germany's Merck hires JP Morgan to sell consumer health
RE
2017Japan's Takeda ready for fresh acquisitions after $5.2 billion Ariad deal
RE
2016TAKEDA PHARMACEUTICAL : Valeant rejected joint takeover bid from Takeda, TPG in spring - s..
RE
Analysis
Takeda, Nintendo among Japanese firms quietly celebrating weak yen
Official Publications
05/11Financial report 
05/11Press Release 
05/11Annual results 
02/033rd quarter report 
02/03Press Release 
02/033rd quarter results 
Upcoming event on TAKEDA PHARMACEUTICAL COMPANY LIMITED
07/28/22Q1 2022 Earnings Release
Upcoming sector events
07/19/22JOHNSON & JOHNSON : Interim 2022 Earnings Release
07/21/22ROCHE HOLDING AG : Interim 2022 Earnings Release
07/28/22PFIZER INC. : Interim 2022 Earnings Release
07/29/22ABBVIE INC. : Interim 2022 Earnings Release (Projected)
Sector
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals